Local Institution
Suwon 443721
0 studies enrolling now · 14 studies all time
What they study most
Acute Coronary Syndrome, Atrial Fibrillation, Atrial Flutter, Chronic Hepatitis B, Diabetes, Diabetes Type 2, Hepatitis B, Chronic, Hepatitis C Virus (HCV), Hepatocellular Carcinoma, Kawasaki Disease, Lung Cancer - Non Small Cell Squamous, Lupus Nephritis
Studies at this site
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
- An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis — Stopped early
- Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed
- Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
- Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC — Completed
- A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease — Completed
- Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
- Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
- Phase III Acute Coronary Syndrome — Stopped early
- Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
- Safety Study of BMS-770767 in Subjects With Type 2 Diabetes — Completed
- A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas — Completed
- Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus — Completed
- Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C — Withdrawn before enrolling